Contineum Therapeutics (NASDAQ:CTNM – Get Free Report) and Indivior (NASDAQ:INDV – Get Free Report) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, dividends, earnings, valuation, profitability, risk and institutional ownership.
Insider & Institutional Ownership
60.3% of Indivior shares are held by institutional investors. 7.9% of Contineum Therapeutics shares are held by insiders. Comparatively, 0.7% of Indivior shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Analyst Ratings
This is a breakdown of current ratings for Contineum Therapeutics and Indivior, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Contineum Therapeutics | 1 | 1 | 4 | 0 | 2.50 |
| Indivior | 0 | 1 | 6 | 0 | 2.86 |
Profitability
This table compares Contineum Therapeutics and Indivior’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Contineum Therapeutics | N/A | -24.73% | -23.51% |
| Indivior | 26.65% | -283.11% | 36.85% |
Earnings & Valuation
This table compares Contineum Therapeutics and Indivior”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Contineum Therapeutics | $50.00 million | 9.45 | -$59.98 million | ($1.73) | -7.26 |
| Indivior | $1.24 billion | 3.41 | $210.00 million | $2.79 | 12.84 |
Indivior has higher revenue and earnings than Contineum Therapeutics. Contineum Therapeutics is trading at a lower price-to-earnings ratio than Indivior, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
Contineum Therapeutics has a beta of 0.75, meaning that its stock price is 25% less volatile than the S&P 500. Comparatively, Indivior has a beta of 0.82, meaning that its stock price is 18% less volatile than the S&P 500.
Summary
Indivior beats Contineum Therapeutics on 10 of the 14 factors compared between the two stocks.
About Contineum Therapeutics
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.
About Indivior
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.
Receive News & Ratings for Contineum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Contineum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
